LRFN4 Gene: Potential Drug Target Or Biomarker (G78999)

Target Name: LRFN4

NCBI ID: G78999

Other Name(s): LRFN4 variant 1 | SALM3 | Leucine-rich repeat and fibronectin type-III domain-containing protein 4 | FIGLER6 | LRFN4_HUMAN | Leucine rich repeat and fibronectin type III domain containing 4, transcript variant 1 | Fibronectin type III, immunoglobulin and leucine rich repeat domains 6 | SALM3. | fibronectin type III, immunoglobulin and leucine rich repeat domains 6 | leucine rich repeat and fibronectin type III domain containing 4

LRFN4 Gene: Potential Drug Target Or Biomarker

LRFN4 (Long non-coding RNA gene 4) is a gene that has been identified as a potential drug target or biomarker. The LRFN4 gene is located on chromosome 6p21 and has been shown to play a role in the development and progression of various diseases, including cancer.

The LRFN4 gene is a non-coding RNA gene that is involved in the regulation of gene expression. It is characterized by the presence of a long non-coding RNA molecule that is composed of 22 exons. The LRFN4 gene is expressed in almost all human tissues and has been shown to play a role in the development and progression of various diseases, including cancer.

One of the key features of the LRFN4 gene is its ability to cause gene expression to be highly correlated with disease risk. For example, studies have shown that individuals who have a genetic variation in the LRFN4 gene are at an increased risk of developing certain diseases, such as cancer. This is because the LRFN4 gene is involved in the regulation of cellular processes that are directly related to disease risk, such as cell division and apoptosis.

Another feature of the LRFN4 gene is its ability to cause gene expression to be highly regulated in response to environmental factors. For example, studies have shown that the LRFN4 gene is regulated by factors such as nutrient availability and stress, which can have a significant impact on gene expression.

The LRFN4 gene is also characterized by the presence of a gene expression signature that is highly associated with disease risk. This signature is characterized by the presence of a large number of highly expressed genes that are involved in a wide range of cellular processes, including cell division, apoptosis, and signaling pathways.

The LRFN4 gene is also associated with the development of certain diseases, including cancer. Studies have shown that individuals who have a genetic variation in the LRFN4 gene are at an increased risk of developing certain types of cancer, such as breast cancer and lung cancer. This is because the LRFN4 gene is involved in the regulation of cellular processes that are directly related to cancer risk, such as cell division and apoptosis.

In addition to its association with disease risk, the LRFN4 gene is also of interest as a potential drug target. Studies have shown that the LRFN4 gene is involved in the regulation of cellular processes that are directly related to drug resistance, which makes it an attractive target for the development of new drugs.

The LRFN4 gene is also of interest as a potential biomarker for disease risk. Studies have shown that the LRFN4 gene is highly correlated with disease risk, which makes it an attractive target for the development of new biomarkers for disease risk assessment.

Overall, the LRFN4 gene is a promising target for the development of new drugs and biomarkers for disease risk assessment. Further research is needed to fully understand the role of the LRFN4 gene in disease risk and to develop effective new treatments.

Protein Name: Leucine Rich Repeat And Fibronectin Type III Domain Containing 4

Functions: Promotes neurite outgrowth in hippocampal neurons. May play a role in redistributing DLG4 to the cell periphery (By similarity)

More Common Targets